Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics

Trial Profile

Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Atorvastatin (Primary) ; Evolocumab (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms FLOREY; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 16 Mar 2018 Results (n=63) assessing the effects of evolocumab against PCSK9 and lowers Lp (a) in subjects with baseline plasma apo (a) concentrations greater than 5nmol per L along with substudy results, published in the European Heart Journal.
    • 30 Aug 2017 Results assessing factorial effects of Evolocumab and Atorvastatin on lipoprotein metabolism, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 21 Aug 2017 According to an Amgen media release, data feom this trial will be presented at the European Society of Cardiology (ESC) Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top